Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(10): 1411-1422, 2017 10.
Article
en En
| MEDLINE
| ID: mdl-28838862
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Tumores Neuroendocrinos
/
Everolimus
/
Neoplasias Gastrointestinales
/
Neoplasias Pulmonares
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2017
Tipo del documento:
Article